


Substitute for form 1449A/PTO

**Complete if Known****INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/501,029
Filing Date	July 25, 2005
First Named Inventor	Zita Jegesne Csakai
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	CytRx/016



U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
KM		US- 4,404,384	09-13-1983	Gebert, et al.	
		US-4,187,220	02-05-1980	Takacs et al.	
		US-4,451,286	05-29-1984	Martin et al.	
		US- 5,147,879	09-15-1992	Nagy, et al.	
		US- 5,239,077	08-24-1993	Bertok, et al.	
		US- 5,278,309	01-11-1994	Bertok, et al.	
		US- 5,296,606	03-22-1994	Nagy, et al.	
		US- 5,328,906	07-12-1994	Nagy, et al.	
		US- 5,334,600	08-02-1994	Van Duzer, et al.	
		US- 6,649,628	11-18-2003	Kurthy, et al.	
		US- 6,653,326	11-25-2003	Vigh, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> "Number" <sup>4</sup> "Kind Code" <sup>5</sup> (if known)				
KM		CA 2059184	07/15/1992	Ciba-Geigy AG		
		EP 0369944	05/23/1990	Ciba-Geigy AG		
		GB 1,540,028	02/07/1979	Hoechst Aktiengesellschaft		
		GB 1,582,029	12/31/1980	Chinoin		
		WO 90/04584	05/03/1990	Biorex		
		WO 90/08131	07/26/1990	Chinoin		
		WO 92/03130	03/05/1992	The Wellcome Foundation		
		WO 95/30649	11/16/1995	Biorex		
		WO 97/00251	01/03/1997	Biorex		
		WO 97/13504	04/17/1997	Medgene Limited		
		WO 97/16439	05/09/1997	Biorex		
		WO 98/06400	02/19/1998	Biorex		
		WO 98/43948	10/08/1998	Biorex		
		WO 00/35914	06/22/2000	Biorex		
		WO 00/50403	08/31/2000	Biorex		
		WO 01/79174	10/25/2001	Biorex		
		WO 05/041965	05/12/2005	Biorex		

9/4/2007

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of

**Complete if Known**


Application Number	10/501,029
Filing Date	July 25, 2005
First Named Inventor	Zita Jegesne Csakai
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	CytRx/016

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
KN		DeKoning, et al., "Org. 2766 improves Functional and Electrophysical Aspects of Regenerating Sciatic Nerve in the Rat," <i>Peptides</i> , 8(3):415-422, (1987)	
		Morrison, et al., <i>Organic Chemistry</i> , Allyn and Bacon, Inc. (Boston), 205-211, (1983)	
		Sorensen H. and Mortensen K., "Soluble expression of recombinant proteins in the cytoplasm of <i>Escherichia coli</i> ," <i>Microbial Cell Factories</i> , 4:1-8(2005)	
		Stanley, "Sensory and Motor Nerve Conduction Velocities and the Latency of the H-Reflex During Growth of the Rat," <i>Experimental Neurology</i> , 71(2):497-506, (1981)	
		Tesfamariam, et al., "Contraction of Diabetic Rabbit Aorta Caused by Endothelium-Derived PGH <sub>2</sub> -TxA <sub>2</sub> ," <i>American Journal of Physiology</i> , 257(5):1327-1333, (1989)	
		Winslow, et al., "Comparative Effects of the Isomers of Bepridil on Isolated Coronary and Aortic Arteries," <i>European Journal of Pharmacology</i> , 166(2):241-249, (1989)	
		Burger, Alfred, "Pro-Drugs," <i>A Guide to the Chemical Basis of Drug Design</i> , p. 15, 1.3.1	
		"Preparation and Spectral Study of O-methyl=benzamidoximes," Beltrao et al., <i>Chemical Abstracts</i> , 89:215038s (1978)	
		"Insecticidal (hydroxyimino)butanones," Showa Denko K.K., <i>Chemical Abstracts</i> , 102:220443m (1985)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



9/4/2007